Amarin Corp. Plc\uk (AMRN) vs its competitors

Amarin Corp. Plc\uk against drug manufacturers general

Amarin Corp. Plc\uk is the 15th largest of 19 graded companies. Showing 5 of them, including AMRN itself. 2 more are in this industry but have no grade yet, so they are left out rather than shown blank.

Company	Grade	Market value	Revenue	Profit margin	Free cash flow	Price to earnings
ELI Lilly And CompanyLLY	A+	$1.12T	$79.7B	33.5%	$18.2B	39.79
Johnson & JohnsonJNJ	A+	$644.8B	$97.9B	21.5%	$22.2B	31.04
AbbVie Inc.ABBV	B	$465.2B	$64.4B	9.8%	$18.2B	74.37
Merck & Co., Inc.MRK	A	$368.3B	$66.6B	4.8%	$16.1B	118.48
Amarin Corp. Plc\ukAMRN	D-	$5.5B	$186.2M	-14.6%	—	—

14 more drug manufacturers general companies

Graded on the same five checks, from their own SEC filings.

A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.

Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Amarin Corp. Plc\uk on the overview — nothing here comes from a data vendor’s own ratios.

Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.